PCSK9 and diabetes mellitus: Notably, a recent systematic review and meta-analysis by González-Lleó et al. (2024) provided reassuring evidence, confirming that PCSK9 inhibitors do not significantly alter glycemic control nor increase the incidence of diabetes in treated patients [13].